Järås et al. [62] showed that in AML, Ck1α partial inhibition promotes p53 activation and leukemic blast elimination, highlighting its crucial role for tumor survival and potential importance as a therapeutic target. The gene discussed is CSNK1A1; the disease is acute myeloid leukemia.